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Abstract 
Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apopto-
sis and regulation of cell cycle. These functional attributes make Survivin a unique protein exhibiting divergent func-
tions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently 
expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated 
in a variety of human cancers. Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a 
decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin 
is an important target for cancer vaccines and therapeutics. Survivin has also been found to be prominently expressed 
on both human and embryonic stem cells and many somatic stem cell types indicating its yet unexplored role in 
stem cell generation and maintenance. Overall, Survivin emerges as a molecule with much wider role in cellular 
homeostasis. This review will discuss various aspects of Survivin biology and its role in regulation of apoptosis, cell 
division, chemo-resistance and tumour progression. Various molecular and immunotherapeutic approaches targeting 
Survivin will also be discussed.
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Background
Cancer is a heterogeneous group of diseases where 
abnormal cell growth with potential to invade other body 
parts takes control of normal homeostasis and becomes 
fatal if not timely and rightly treated. While standard 
treatments like surgery, chemotherapy or radiotherapy 
have significantly improved the disease outcome, occur-
rence of drug resistance and metastatic spread of the 
disease still remains a tough challenge. Substantial data 
suggests that immunotherapy could serve as a powerful 
weapon to prevent metastatic spread of cancer. Immu-
notherapy specifically targets tumor cells thereby avoid-
ing collateral damage to non-tumor cells. Induction of 
anti-tumor response also has the potential to eradicate 
tumor at distant sites in the body which may not be pos-
sible by surgical resection. Induction or enhancement of 
anti-tumor immune response is a formidable challenge in 
cancer because tumor cells use multiple evasion strate-
gies and avoid being detected or eliminated by immune 
cells. Resistance to apoptosis is one important evasion 
mechanism by which tumour cells escape detection 
by immune cells and promote their proliferation at the 
same time. Therefore, molecules involved in regulation 
of apoptosis can be potential targets for tumor therapy 
including immunotherapy.
Inhibitor of apoptosis protein family (IAPs) is an 
important group of proteins involved in regulation of 
apoptosis. IAPs also have an important role in regula-
tion of T cell responses in anti-tumor immunity. One 
member of this protein family, Survivin occupies a key 
position because of overexpression in cancer cells. It is 
speculated that Survivin overexpression in tumor cells 
promotes tumor progression by multiple pathways such 
as dysregulation of apoptosis and cell division, altered 
sensitivity to antitumor drugs or promoting survival of 
cancer stem cells. Survivin can serve as a universal tumor 
antigen because it is expressed in most human malig-
nancies and has the potential to trigger immune effec-
tor responses. Therefore, blocking Survivin function by 
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various immunotherapeutic or molecular approaches is 
emerging as a promising therapeutic strategy in cancer. 
This review will discuss various aspects of Survivin biol-
ogy and multiple approaches to block Survivin in tumor 
cells.
IAP family and Survivin
Inhibitors of apoptosis (IAP) family of proteins are found 
in almost all species from lower to higher vertebrates. 
Initially identified in baculoviruses as apoptotic suppres-
sors, eight IAP homologs namely neuronal apoptosis 
inhibitory protein (NAIP), baculoviral IAP repeat-con-
taining protein 2/human inhibitor of apoptosis protein-2 
(c-IAP1/HIAP-2), baculoviral IAP repeat-containing pro-
tein3/human inhibitor of apoptosis protein-1 (c-IAP2/
HIAP-1), X-linked inhibitor of apoptosis (XIAP), IAP-
like protein 2 (ILP2), melanoma inhibitor of apoptosis 
protein (MLIAP), Survivin, and BIR repeat-containing 
ubiquitin enzyme system (BRUCE) have been identi-
fied in humans till date [1–10]. IAPs are functionally and 
structurally similar and function in regulation of pro-
grammed cell death [11–13]. Since IAPs are an impor-
tant protein family which regulate cell fate in response to 
stress signals or genomic instability, therefore any dysreg-
ulation in IAP function has an obvious association with 
cancer development, induction of oncogenesis or drug 
resistance [14]. Investigating the mechanism of action of 
IAPs in cancer has provided important leads for antican-
cer drug development.
Structurally, all members of IAPs contain approxi-
mately 70 amino acid long Baculovirus IAP Repeats (BIR) 
domains at the N-terminus, which are essential but not 
sufficient for their anti-apoptotic activity [15]. Although 
the number of BIR domains varies among IAP members, 
each BIR domain is made up of cysteine and histidine res-
idues in a well-defined pattern (Cx2Cx6Wx3Dx5Hx6C), 
which represents a novel zinc-binding fold. In addition 
to BIR domain, several viral, mammalian and insect IAPs 
require a ring finger domain (RING) near the C-terminus 
for suppression of apoptosis [9, 16]. However, C-terminal 
RING is not indispensable for suppression of apoptosis 
by human c-IAP1, c-IAP2 and XIAP [17, 18]. Human 
cIAP-1 and cIAP-2 also contain a Caspase Recruitment 
Domain (CARD), significance of which is not clearly 
understood during apoptosis suppression. IAPs also pos-
sess additional domains; ubiquitin-associated (UBA) 
domain (in c-IAP1, c-IAP2, XIAP and hILP2) and ubiqui-
tin-conjugating (UBC) domain (in BRUCE/APOLLON), 
these domains assist in inducing ubiquitination and pro-
teasome degradation of specific caspases and suppression 
of apoptosis [6, 19, 20]. Of all the IAPs known so far, Sur-
vivin is the smallest IAP protein with a single N-terminus 
BIR domain and C-terminus Coiled Coil (CC) domain. 
As compared to other IAPs, Survivin exhibits most 
restricted expression in adult tissues and has crucial role 
in regulating both cell division and apoptosis. It is highly 
expressed in most human cancers but not in normal, ter-
minally differentiated adult tissues, thus making Survivin 
an exciting new tumour marker [5].
Molecular organization and structure of Survivin
Survivin is encoded by BIRC5 gene and consists of 4 
exons and 3 introns covering 14,796 nucleotides on 
chromosome 17q25 forming transcripts with varied 
functional domains. The BIRC5 gene encodes wild type 
Survivin (WT, four exons; 142 amino acid) and five 
known additional splice variants i.e.; ΔEx3 (Survivin 
with deletion of exon 3; 137 amino acid), 2B (Survivin 
with an additional exon; 165 amino acids), 3B (five exons; 
120 amino acid), 2α (2 exons;74 amino acids), 3α (two 
exons;78 amino acids) [21–23]. All Survivin isoforms 
share complete sequence identity in the N-terminus 
region, including some or the entire BIR domain, but 
they differ in the carboxyl end [24]. Figure  1 illustrates 
the various splice variants of Survivin and the amino acid 
alterations present in each splice variant. Survivin iso-
forms also have different expression patterns and cellular 
localization as compared to wild type form, Survivin-
ΔEx3 is found predominantly in the nucleus where as 
Survivin- 2B is found in the cytoplasm. Alternative splic-
ing of Survivin has been shown to have correlation with 
disease activity in various patient studies. Survivin WT, 
2B and ΔEx3 variants have been extensively investigated 
for clinical and prognostic association in cancer. Presence 
of ΔEx3 variant has been associated with unfavourable 
clinical outcome and prognosis [25]. Conflicting data 
exists for clinical and pathological correlation of variant 
2B in cancer; certain studies demonstrate association 
of 2B variant with aggravated disease and poor survival 
[26] while some studies indicate that presence of 2B vari-
ant is associated with less severe disease [27]. Overall, 
there is a consensus that ΔEx3 is anti-apoptotic and 2B is 
pro-apoptotic and that these variants may perform con-
trasting functions in tumor progression and response to 
therapy [28]. Presence of Survivin isoforms has also been 
shown to influence angiogenesis. In a study by Doucette 
T et al., presence of Survivin splice variant 2 was associ-
ated with poorer survival and promoted malignant pro-
gression, angiogenesis, and shorter tumor-free survival in 
mouse model of glioma [29].
It still remains unclear whether alternative splicing of 
Survivin is an adaptation used by cancer cells to sup-
port their proliferation and avoid detection by immune 
surveillance Association of splice variants with distinct 
pathological and survival outcomes indicate possible role 
of these variants in disease progression. However, relative 
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contribution of different splice variants of Survivin with 
tumorigenesis, immune evasion and response to ther-
apy is not completely understood and warrants further 
investigation.
Cellular localization of Survivin
Survivin is predominantly present in the cytosol of 
tumour cells. However, a smaller nuclear fraction of 
Survivin localizing to kinetochores of metaphase chro-
mosomes has also been reported in tumour and prolif-
erating cells, indicating that these different subcellular 
pools of Survivin may have different functions [30, 31]. 
Cytosolic Survivin is believed to function as apoptotic 
suppressor while nuclear Survivin is postulated to regu-
late cell division. However, the pathological significance 
of nuclear Survivin as a favourable prognostic marker 
for tumour cells is still debatable. There is equivocal data 
from patient studies to indicate nuclear/cytosolic Sur-
vivin expression as an unfavourable or favourable prog-
nostic marker in cancer [31]. Apart from cytosolic and 
nuclear pool, Survivin has also been detected in mito-
chondrion [32] and shown to be released into cytosol in 
response to cellular stress stimuli and suppress caspase 
activation [32]. Extracellular pool of Survivin has also 
been shown to exist as exosomes in form of 40–100 nm 
membrane vesicles secreted from tumour cells and taken 
up by surrounding cells [33]. In fact, many IAPs such as 
cIAP1, cIAP2 and XIAP including Survivin have been 
shown to exist as tumour exosomes in cancer cell lines 
[34]. Exosomes containing Survivin have been shown to 
re-enter cells and promote tumour growth. Khan et  al. 
have demonstrated that extracellular pool of Survivin has 
the ability to cause neighbouring cancer cells to increase 
resistance to therapy, rapidly proliferate, and acquire an 
increased potential to become invasive in vitro [35, 36]. 
Increased levels of plasma derived exosomal Survivin 
from prostate cancer patients has been shown to cor-
relate with disease severity [37]. Thus, both intracellular 
and extracellular release of Survivin in cancers may be 
responsible for aggravated disease.
Multiple roles of Survivin
Survivin and cell proliferation
Regulation of cell division is recognized as promi-
nent function of Survivin. Normal cells show cell cycle 
dependent synthesis, expression and degradation of Sur-
vivin. Survivin forms an integral component of chromo-
somal passenger complex (CPC) which ensures proper 
segregation of chromosomes and cytokinesis during 
cell division [38]. Various checkpoints ensure nuclear 
division, attachment to mitotic spindle and cytokine-
sis. CPC is a hetero-tetrameric complex which local-
izes to different sites at different times during mitosis, 
this serves to regulate key events in cell division such as 
Fig. 1 Alternative splice variants of Survivin encoded by BIRC5 gene. Schematic representation of exons encoding five isoforms of Survivin. Note 
the breaks in the middle denote introns 1–3. Wild type (WT) is coded by exons 1–4 and is 142 amino acid (aa) long. An additional 69 bp exon 
between exons 2 and 3 results in Survivin 2B, making it a total of 67 aa in length. Exon 3 deletion leads to a frame shift variant resulting in a 3′ UTR, 
forming Survivin ΔEx3, 137 aa in length. Survivin 3B is formed by addition of 7 aa at the C-terminal, exon 3B from intron 3, the first 113 aa are con-
served from WT Survivin. Variants 2α and 3α have a 3′UTR along with exons 1–2 and are 74 and 78 aa in length respectively
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chromosome-microtubule attachment, proper spindle 
assembly and occurrence of cytokinesis. Aurora B kinase 
is the enzymatic component of CPC whereas as the other 
three components; inner centromere protein (INCENP), 
Survivin and Borealin (also known as Dasra) have regula-
tory and targeting functions. Alteration in any of the four 
components can lead to a defect in chromosomal segre-
gation and/or cytokinesis and cause genomic instability 
[39–42]. Analysis of individual contributions of these 
proteins to formation of CPC suggests that the enzy-
matic component Aurora B kinase is directed to mitotic 
cell by the other three proteins of CPC i.e. INCENP, 
Survivin and Borealin/Dasra. INCENP acts as a scaffold 
protein and stabilizes the complex, Borealin acts to pro-
mote binding of Survivin to INCENP and Survivin acts as 
a determining factor in centromere localization of CPC 
[43, 44]. Although Survivin acts as a key protein in medi-
ating CPC targeting, other protein components of CPC 
act to promote a stable structure. Furthermore, a distinct 
pool of subcellular Survivin is associated with polymer-
ized tubulin and regulates microtubule formation during 
cell division.
Survivin as an inhibitor of apoptosis
Overexpression of Survivin inhibits both intrinsic and 
extrinsic pathways of apoptosis [5, 45–48]. Depletion of 
Survivin in human cells induces defects in apoptosis and 
multiple defects in cell division [38, 49]. Although the 
mechanism of inhibition of apoptosis by Survivin is still 
unknown, both direct and indirect binding of Survivin to 
initiator or effector caspases is supposed to contribute to 
inhibition of apoptosis by Survivin [50]. Direct binding of 
Survivin to effector caspase-3 has been speculated, how-
ever, unlike other IAPs, Survivin does not possess the 
structural moiety responsible for docking of caspase-3 to 
the BIR domain [51]. Some studies suggest that Survivin 
binds directly to caspase-9 and inhibits its activity [52]. 
Another mechanism proposed for Survivin mediated 
inhibition of caspase- 9 is binding of hepatitis B X-inter-
action protein (HBXIP) to procaspase-9. It is also specu-
lated that X-linked IAP (XIAP) which also contains BIR 
domain leads to an inhibition of caspase- 9 along with 
Survivin [53, 54]. In yet another mechanism, Survivin 
inhibits intrinsic (mitochondrial) pathway of apoptosis 
by binding to pro-apoptotic proteins called Secondary 
Mitochondria-derived Activator of Caspase (SMAC/
DIABLO). SMAC/DIABLO are released during intrinsic 
pathway from mitochondria and activate caspase-9 to 
induce apoptosis. Survivin binds to SMAC/DIABLO and 
prevents caspase activation [52]. Song et al. have demon-
strated that Survivin physically associates with SMAC/
DIABLO and blocking this interaction induced apoptosis 
in taxol treated HeLa cells [55].
Taken together, there is substantial evidence to sup-
port the dual function of Survivin i.e. as a regulator of 
cell division and inhibitor of apoptosis (Fig. 2). Wheatley 
SP reported that the C-terminus of Survivin is required 
for cell division and the N- terminus is dispensable for 
apoptosis [56]. Though, thought as two separate func-
tions, it may be possible that Survivin expression acts as a 
vital checkpoint for induction of programmed cell death 
in those cells undergoing aberrant cell division. More 
studies will be required to confirm whether Survivin 
exclusively acts as a regulator of cytokinesis or cell death 
in normal cells and whether either of these functions 
becomes predominant during tumor progression.
Role of Survivin in supporting angiogenesis, metastasis 
and chemo‑resistance of tumor cells
One of the pathways responsible for Survivin medi-
ated tumor progression is promotion of angiogenesis in 
cancer cells. Survivin upregulates VEGF expression and 
promotes endothelial cell (ECs) proliferation by mecha-
nisms which are still not clear [57]. Existence of a positive 
feedback loop connecting Survivin expression in tumor 
cells to PI3K/Akt enhanced β-catenin-Tcf/Lef-dependent 
transcription inducing secretion of VEGF and angiogen-
esis has been suggested [57]. Knockdown of Survivin 
in glioma has been shown to inhibit angiogenesis [58]. 
Small interfering RNA (siRNA) mediated silencing of 
Survivin sensitized human breast cancer cells to apopto-
sis and inhibited tumour formation and angiogenesis in 
breast or cervical cancer xenograft model in  vivo [59]. 
Survivin induced VEGF expression also contributes to 
chemo-resistance by stimulating organization of tubulin 
into distinct fibres [60]. Survivin is particularly upregu-
lated on tumor vascular ECs as compared to normal tis-
sues, thus conferring drug resistance on tumor vascular 
ECs [61]. Therefore, targeting Survivin in tumor will pro-
mote not only tumor cell death but also sensitize cells of 
tumor vascular network to chemotherapeutic drugs.
Survivin may also cooperate with other IAP mem-
bers to promote metastasis. Survivin overexpression 
enhanced migration of human melanocytes and mela-
noma cells on fibronectin whereas Survivin knockdown 
under sub-apoptotic conditions blocked their migration 
and invasion [62]. Inter-molecular interaction between 
XIAP and Survivin promoted tumor cell invasion in vitro 
and metastatic dissemination in  vivo in murine model 
of breast cancer and rat insulinoma. This pathway oper-
ated independent of the role of IAPs in cell survival. Sig-
nal transduction through this pathway resulted in NF-κB 
activation, transcriptional upregulation of fibronectin, 
autocrine/paracrine signalling by β1 integrins, and con-
stitutive phosphorylation, i.e. activation of cell motility 
kinases i.e.; FAK and Src. implicating direct involvement 
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of IAPs in promoting metastasis. Most significantly, sig-
nal transduction via this pathway did not induce the tra-
ditional epithelial-mesenchymal transition (EMT) but 
rather induced an adhesion gene signature and many 
fold increase in expression of fibronectin gene in tumor 
cells [63]. Survivin has also been shown to enhance mela-
noma cell metastasis through integrin upregulation [64]. 
Survivin promoted breast cancer lymphatic metastasis 
through cooperation with vascular endothelial growth 
factor-C (VEGF-C) [65]. Many patient studies have also 
indicated that overexpression of Survivin correlates 
with increased tumour invasion and metastasis [66, 67], 
thereby implicating a wider role for Survivin beyond reg-
ulating apoptosis and cell division of cancer cells.
Survivin and cancer stem cells
Existence of cancer stem cells has been proposed as a 
primary reason for genesis of cancer and disease relapse. 
It is hypothesized that tumours are maintained by a sub-
set of tumour stem cells that possess the self-renewal 
capacity similar to stem cells. Role of Survivin has been 
shown in regulation of adult stem cell physiology such 
as in haematopoietic stem cells, neuronal stem cells or 
intestinal stem cells [68–70]. Survivin is also important 
for embryonic stem cell and totipotent stem cell func-
tion [71]. Since normal stem cells and cancer stem cells 
share common features, it is plausible to assume that like 
normal stem cells, Survivin expression on cancer stem 
cells may also be involved in regulating cancer stem cell 
behaviour.
An investigation of co-expression of Survivin and stem 
cell specific proteins in oesophageal squamous cell car-
cinoma (ESCC) patients revealed that patients exhibiting 
high expression of both a stem cell specific protein Oct-4 
and Survivin showed worst prognosis. Survivin expres-
sion correlated with Oct-4 expression in ESCC cells sug-
gesting a regulation/interaction between Survivin and 
Oct-4 [72]. Molecular mechanisms underlying the inter-
action/regulation between Survivin and stem cell specific 
proteins are still not properly understood. Role of Sur-
vivin is also implicated in specifically regulating genes 
involved in leukemia cancer stem cell (LCSC) fate and 
not normal hematopoietic stem cell (HSC). This differ-
ence in Survivin signalling in LCSC vs HSC opens new 
avenues for specific therapeutic targeting and elimination 
of cancer stem cells [73].
Survivin as therapeutic target in cancer
Survivin commands a central position among IAPs as 
being both a regulator of cell division and apoptosis. 
However, normal differentiated cells have very low or 
no expression of Survivin. Does low or no expression of 
Fig. 2 Unique role of Survivin in both apoptosis and cell division. Survivin expression in cytosol or mitochondrion can suppress both extrinsic and 
intrinsic pathways of apoptosis. Survivin expression in nucleus plays an important role in regulation of cell division by acting as an important com-
ponent of chromosome passenger complex (CPC)
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Survivin on normal cells have any correlation with cel-
lular functions or less cell division/apoptosis in normal 
cells? Survivin knock-out mice exhibit embryonic lethal-
ity [74], loss of self-renewing bone marrow progenitor 
cells and bone marrow ablation [75]. Conditional dele-
tion of Survivin in thymus leads to a developmental block 
in thymocytes at double negative stage and presence of 
immature T cells in periphery [76]. Survivin also emerges 
as a key regulator of clonal expansion of Teff cells [77], 
proliferation of early B cell progenitors and activated 
mature B cells [78], erythroid [79] and megakaryocyte 
differentiation [80]. Survivin appears to be an intrigu-
ing protein regulating functions of various immune cells, 
hence therapeutic approaches aimed at targeting Sur-
vivin need to be carefully evaluated.
Therapeutic approaches targeting Survivin
Due to important role of Survivin in tumor cell divi-
sion, apoptosis, chemo resistance and cancer stem cell 
survival; therapeutic blockade of Survivin in tumor cells 
may possibly yield cumulative benefits. Various strate-
gies have been envisaged to block the expression or func-
tion of Survivin in tumour cells (i) immunotherapeutic 
approaches to induce immune response against Survivin, 
(ii) small molecule inhibitors/antagonists to block func-
tion of Survivin, (iii) nucleic acid based approaches which 
interfere with Survivin gene expression or (iv) gene abla-
tion of Survivin to regulate cell cycle and apoptosis.
Survivin based Immunotherapeutic approaches
Manipulation of host immune system to produce an anti-
tumour response is known as immunotherapy. This con-
cept was first pioneered by William Coley (1891) who 
used extracts of S. pyogenes and heat-killed Bacillus pro-
digious (now reclassified as Serratia marcecsens) bacteria 
to treat sarcomas [81]. Coley’s experiments established 
that immune stimulatory components present in “Coley’s 
toxins” boosted anti-tumor immune response and 
induced disease remission in cancer. Coley’s experimen-
tal results were widely criticized and concept of immu-
notherapy was totally dismissed as an effective strategy to 
control cancer. Alternative treatment modalities in can-
cer like chemotherapy and radiotherapy which had been 
well developed by that time presented with drawbacks of 
inducing disease resurgence and toxicity. Simultaneously, 
with better understanding of principles of immunology, 
it was apparent that immune system had a crucial role in 
controlling certain types of cancer. As various principles 
of immunology were being unravelled, it became clear 
that immunotherapy is a better therapeutic option as 
compared to chemotherapy or radiotherapy because it is 
specific for tumor cells and is devoid of side effects.
Immunotherapy eliminates tumor cells by initiating/
boosting anti-tumor immune response or reversing 
inhibitory immune signalling. Active immunotherapy 
involves development of a targeted anti-tumor immune 
response in the host using specific cancer antigens or 
ex  vivo expansion of effector cells and infusion back 
into the patient. Passive immunotherapy covers transfer 
of preformed molecules such as therapeutic antibodies 
or antigen specific T cells which can eliminate or sup-
press tumor. A number of monoclonal antibodies against 
growth factor receptors or antigenic determinants on 
cancer cells have been successfully translated for thera-
peutic usage in various cancers. Recent success of anti-
bodies targeting inhibitory immune checkpoints such as 
CTLA-4 and PD-1 has again shifted the focus on inhibi-
tory molecules in immune cell signalling for a beneficial 
anti-tumor response [82]. Although, diverse approaches 
for therapeutic cancer vaccines have shown good immu-
nogenicity in clinical trials yet clinical translation of anti-
gen specific cancer vaccines has not been as successful as 
passive immunotherapy. The rationale for cancer vaccine 
is to target a specific tumor antigen as vaccine candidate, 
induce robust antigen presentation mostly through DCs 
and induction of cytotoxic T cell (CTL) response. Tumor 
antigens are processed into peptides, loaded onto MHC 
molecules and MHC-peptide complex is presented by 
antigen presenting cells (APCs) to T cells for activation. 
Induction of effector T cell response is sequential; anti-
gen specific T cells are first primed in the secondary lym-
phoid organs through the interaction with APC. APCs 
particularly dendritic cells (DC) sample antigens from 
tumor cells and present antigens to CD4+  T cells via 
the MHC class-II pathway or to CD8+ T-cells via cross 
presentation or cross priming [83, 84]. This antigen rec-
ognition in association with MHC is insufficient to effec-
tively activate T cells; APC provide additional co-signals 
that regulate the breadth of T cell activation. These mul-
tiple co-signals can be induced by stimulatory (CD80/
CD86:CD28) and inhibitory molecules also known as 
“Immune checkpoints” [85, 86]. Antigen specific T cells 
once primed by APCs will scan for cognate MHC-pep-
tide on target tumor cells and execute lysis of target cells. 
Immunotherapy using specific cancer antigens serves 
to expand the population of antigen specific T cells 
so that immune escape of tumor is prevented (Fig.  3). 
The vaccine strategies employ either peptides or whole 
recombinant protein in adjuvant, recombinant viruses 
encoding the antigen of interest or other recombinant 
microorganisms, DNA vaccines, cytokine or co-stimula-
tion enhanced vaccines, killed tumor cells, or DCs pulsed 
with protein-or peptide. Incorporating a strong adjuvant 
enhances tumor antigen presentation and activation of 
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immune effector mechanisms leading to induction of a 
robust CTL response against tumor cells.
An ideal cancer vaccine should use an antigen which is 
specific and overexpressed on tumor cells. Survivin has 
emerged as an ideal antigen for cancer immunotherapy 
because of tumour specific expression and critical role 
in regulating cell division and apoptosis of tumour cells. 
[87–89]. Human transcriptome analysis reveals that Sur-
vivin is the fourth most highly expressed transcript in 
human cancer cells when compared to normal cells [90]. 
Overexpression of Survivin has been associated with an 
unfavourable prognosis in colorectal and bladder can-
cers and neuroblastoma [91, 92], melanoma and non-
melanoma skin cancers [93, 94]. Survivin overexpression 
also induces an increased chemotherapeutic drug resist-
ance as discussed earlier in the review. Survivin expres-
sion confers a survival advantage on tumour cells and can 
be a universal therapeutic and diagnostic target for all 
tumours.
Survivin protein has been shown to induce CTL 
response in vitro when processed and presented by den-
dritic cells [95] and Survivin derived peptides prime 
CTLs in  vivo in murine model of melanoma [96]. Gen-
eration of Survivin specific CTLs that can lyse HLA 
matched tumour target cells has been demonstrated 
in cancer patients [97]. Presence of spontaneous CTL 
response against MHC-I restricted peptide antigens 
derived from Survivin in patients suffering from mela-
noma, breast cancer and leukemia strongly indicates that 
CD8 T cell restricted epitopes from Survivin are of sub-
stantial immunotherapeutic value [98–100]. Induction 
of effective CTL response was also coupled with homing 
of Survivin specific CTLs to the site of tumour in situ in 
melanoma and breast cancer [101] representing a com-
plete synchronization of both local and systemic immune 
response when using Survivin as a vaccine candidate.
Vaccine approaches such as dendritic cell based (DC) 
vaccines, DNA vaccines [102], peptide vaccines or VLP 
based vaccine for Survivin have also been evaluated in 
preclinical or clinical studies. A DC vaccine trial con-
ducted on non-small cell lung carcinoma (NSCLC) 
patients who received autologous DCs pulsed with apop-
totic bodies of NSCLC showed immunological responses 
in 4/7 stage III unresectable, and 6/7 stage I/II surgically 
resected patients [103]. Another vaccine for HLA-A24 
positive patients was developed by immunizing HLA-
A24 restricted Survivin peptide 2B80–88 which induced 
peptide specific CTL response in urothelial [104], oral 
[105], colorectal [106] and breast cancer [107] patients 
with no adverse effects. In another study, same peptide 
was combined with IFN alpha and immunised in urothe-
lial cancer patients but had no better results as com-
pared to peptide alone [108]. The peptide alone had low 
immunogenicity and the investigators concluded that 
combining the peptide with adjuvants such as heat shock 
proteins, cytokines etc. may boost immune response to 
the peptide [107]. A combination of HLA restricted Sur-
vivin peptides has also been tested in a phase II trial on 
metastatic melanoma patients who showed prolonged 
survival post treatment [109]. A multi-epitope vac-
cine approach using cocktail of five Survivin peptides: 
EMD640744 and Montanide(®) ISA 51 VG as an adju-
vant resulted in anti-Survivin specific T cell responses 
in patients with solid cancers [110]. A liposome based 
Fig. 3 Immunotherapy in cancer. The self-defence of tumors overweighs the anti-tumor immunity leading to clinical manifestations of cancer. The 
various immunotherapeutic approaches are adopted to reverse this imbalance
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formulation of Survivin known as DPX-Survivac has also 
shown to induce Survivin specific immune response in 
patients with ovarian cancer [111].
Although CTL responses are critical for elimination of 
tumour cells, role of CD4 T cells and antibodies is also 
important in modulating anti-tumour immune responses 
[112]. A number of studies have also shown the impor-
tant role of CD4 T cells acting as crucial helper cells to 
boost CTL function and enhance anti-Survivin immune 
response [113, 114]. Presence of HLA-class II epitopes to 
stimulate T helper cell response has been demonstrated 
in Survivin peptides [115, 116]. Sharma et al. have dem-
onstrated an indispensable role of CD4 T cells in sustain-
ing primary and memory anti-tumour immune response 
in a vaccine formulation containing Survivin evaluated in 
a transplantable murine model [117]. Importantly, CD4 T 
cells were crucial in the priming phase of CTLs but not 
during the effector phase of CTL response. In another 
important study by Hoffmann et  al. recombinant fowl 
pox virus encoding Survivin derived class I (H1vax1) and 
class II (H1vax2) derived peptides were designed and 
evaluated for preclinical efficacy in co-culture experi-
ments using dendritic cells and T cells isolated from 
healthy donors. These vaccine constructs showed activa-
tion of both antigen specific CD4 and CD8 T cells and 
cytotoxic activity against Survivin-overexpressing meso-
thelioma cancer cells [118]. Table 1 summarizes the key 
conclusions obtained from various Survivin vaccines 
evaluated in preclinical studies or clinical trials. Preclini-
cal studies with Survivin as vaccine candidate indicate 
induction of an effective anti-tumor response in animal 
models of solid or haematological malignancies and sup-
port the notion that Survivin is immunogenic in humans. 
However, the immunogenicity may be low enough to 
provide protection against tumor cells, therefore antigen 
delivery and role of adjuvants is important to enhance 
immunogenicity of this protein Furthermore, both CD4 
and CD8 restricted epitopes from Survivin protein are 
important for induction of effective anti-tumour immune 
response.
We have also evaluated full length recombinant Sur-
vivin protein as a vaccine candidate with Mycobacterium 
indicus pranii (MIP) as an adjuvant in 4T-1 mouse model 
of breast cancer. MIP has been shown to act as an excel-
lent immune-modulator in animal models for psoria-
sis, lung cancer and exercises anti-tumor action against 
Sp2/0 (myeloma) and EL4 (thymoma) in mice models 
[119]. Subcutaneous administration of MIP-Survivin gen-
erated a tumour protective response and tumour regres-
sion in 4T-1 model of breast cancer in a dose dependent 
manner. MIP as an adjuvant was able to induce a good 
anti-Survivin antibody titre after immunization with 
recombinant murine Survivin protein. MIP also has been 
shown to induce DC activation and enhance antigen 
presentation [120]. Therefore, we propose that combin-
ing full length recombinant Survivin with MIP may gen-
erate epitopes which can activate both Survivin specific 
CD8 and CD4 T cells and induce an effective cell medi-
ated immune response. In addition to mediating a direct 
cell mediated attack of tumour cells, immunization with 
recombinant Survivin in mice also elicited production of 
anti-Survivin antibodies. Pre-existing titre of anti Sur-
vivin antibodies in Balb/c mice immunized with recom-
binant Survivin may also have a role in mediating tumour 
regression in these mice when transplanted with synge-
neic 4T-1 cells. Our data suggests that a combination of 
Survivin and MIP may potentiate anti-tumour immune 
response (Garg et al. Manuscript under preparation).
There is limited data on therapeutic efficacy of antibod-
ies against intracellular antigens; however a study from 
Guo et  al. indicates that intracellular antigens can also 
be targeted by antibodies, thereby widening the scope of 
targeting both extracellular and intracellular tumour anti-
gens by antibody immunotherapy [121–123]. While direct 
evidence for role of anti-Survivin antibodies in inducing 
therapeutic response is lacking, it is possible that induc-
tion of anti-Survivin antibodies after antigen immuniza-
tion may block the overexpression of Survivin on cancer 
cells or inhibit Survivin expressed on exosomes. Anti-
bodies against Survivin may also promote NK cell lysis 
of tumor cells. Spontaneous humoral response against 
Survivin has also been observed in sera of patients of 
lung, gastrointestinal and colorectal cancer [124]. Impor-
tantly, immune response against Survivin (T cell specific 
or antibodies) was absent in healthy individuals [97, 124] 
implying that immune response elicited after Survivin 
vaccination is tumour specific and devoid of autoimmune 
manifestations. Detailed studies will be required to inves-
tigate the effect of Survivin immunization on function of 
immune effector cells as Survivin has important regula-
tory role in T cell and B cell effector responses.
Small molecule inhibitors of Survivin
Several small molecule inhibitors targeting Survivin 
have also been evaluated in various in vitro and in vivo 
studies. Despite the challenges associated with small 
molecule drug development, these inhibitors are impor-
tant for understanding Survivin biology and anti-cancer 
drug development [134, 135]. YM-155 is a novel small 
molecule which suppresses transactivation of Survivin 
through direct binding to its promoter [136]. It selec-
tively suppresses expression of Survivin and induces 
apoptosis in p53-deficient cancer cells in  vitro [136].
YM155 has also shown to be effective in in vivo models 
of prostate, pancreatic, and lung cancer [136–138]. Ter-
ameprocol (EM-1421), a plant derived small molecule is 
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a novel transcription inhibitor which suppresses Survivin 
gene expression and induces apoptosis of cancer cells 
[139]. It is in Phase II safety studies as a vaginal ointment 
in HPV-linked cervical intraepithelial neoplasia [140]. 
GDP366 is a novel small molecule compound which 
potently and selectively inhibited the expression of both 
Survivin and Op18; an onco-protein [141]. Another small 
molecule Survivin inhibitor FL118 exhibited superior 
antitumor efficacy in human tumor xenograft models in 
comparison to standard anti-cancer drugs [142]. Anti-
sense approaches to block Survivin have also been tested. 
LY2181308, a novel 2′-O-methoxymethyl modified anti-
sense oligonucleotide (2-MOE-ASO), is a specific inhibi-
tor of Survivin mRNA and being investigated for efficacy 
in clinical trials in various groups of cancer patients [143]. 
Ribozyme mediated approaches have also been evaluated 
for inhibition of Survivin expression. Down-regulation of 
human Survivin gene expression and increased apoptosis 
was achieved by using two hammerhead ribozymes (RZ-
1, RZ-2) targeting human Survivin mRNA [144]. Specific 
Survivin small interfering RNA (siRNA) also inhibited 
Survivin expression in HL-60 cells and augmented ability 
of HL-60 cells to overcome drug resistance [145]. siRNA 
aimed at blocking Survivin-hsp90 connection have also 
shown anti-cancer effects in androgen independent pros-
tate cancer models [146]. Adenovirus delivered Survivin 
dominant negative mutants (double point mutant (TC34, 
84AA) mediated hepatocellular carcinoma suppression 
[147]. Another dominant negative mutant (GST-tagged 
dominant-negative Survivin protein (dNSurR9-C84A) 
constructed by mutation of Cys84 to Ala in the extreme 
C-terminal region of the BIR domain of Survivin com-
pletely abrogated Survivin’s ability to inhibit apoptosis in 
cancer cell lines [148]. Almost all small molecule inhibi-
tors of Survivin have been designed based on protein- 
protein interactions between Survivin and other partner 
proteins. Since Survivin functions through multiple 
mechanisms using a variety of partner proteins, blocking 
one pathway may not entirely lead to reduction of Sur-
vivin signalling. Substantial evidence exists in cancer cells 
for compensatory proliferative mechanisms to override 
when one signalling pathway is inhibited.
Small molecules are cost effective and have short 
development time as compared to immunotherapeutic 
approaches. Therefore, there is enough reasoning to 
discover and improve existing small molecule inhibi-
tors of Survivin. Immunotherapy approaches, although 
complex in terms of translational development, are 
specific and have long lasting effects. However, tumor 
adaption and immune evasion is one bottleneck to suc-
cess of immunotherapy strategies. Moreover, either 
small molecule or immunotherapy targeting Survivin 
alone has not demonstrated a completely curative 
response therefore a synergistic combination of small 
molecules with immunotherapy may be explored to 
induce and sustain tumor elimination over a course of 
time.
Conclusions
Survivin has emerged as a unique and nodal molecule 
mediating diverse roles in cancer cells. However occur-
rence of different subcellular pools and splice variants 
of Survivin complicate the biology of this molecule. 
Occurrence of particular splice variants in various 
stages of tumor development needs to be thoroughly 
investigated for therapeutic translation of Survivin 
blocking approaches. It is also intriguing to note that 
differential cellular localization of Survivin has differ-
ent functional outcomes. While its role in cell division 
and apoptosis has been substantially investigated there 
is still paucity of data on contribution of Survivin to 
immune evasion by tumor cells. Circulating tumor cells 
also express high levels of Survivin and may also be 
responsible for immune escape of tumor cells. Chronic 
inflammation and immune evasion may work synergis-
tically to induce Survivin upregulation on tumor cells. 
Nonetheless, there has been an increasing interest to 
develop immunotherapeutic approaches targeting Sur-
vivin because of its prominent role in cancer develop-
ment and ability to induce an effective CTL response. 
Several studies have shown promising results in preclin-
ical evaluation while some have advanced to stage- I or 
-II clinical trials. The safety and toxicity profile for Sur-
vivin has also shown promising outcome. Figure 4 sum-
marizes conceivable benefits of using Survivin inhibitors 
or immunotherapeutic approaches using Survivin as an 
antigen. Given the tremendous heterogeneity in human 
cancers, translational development for Survivin based 
vaccines or inhibitors of Survivin may even show better 
results if used in combination with traditional therapies. 
Combinatorial therapy using Survivin as vaccine and 
immune checkpoint blockade (PD-1, CTLA-4 etc.) may 
also be considered for an efficient anti-tumor immune 
response.
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